Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression

Cell Reports

Volumn 10, Issue 3, 2015, Pages 383-397

  deVries, Nienke A ^a   Hulsman, Danielle ^a   Akhtar, Waseem ^a   deJong, Johann ^a   Miles, Denise C ^a   Blom, Marleen ^a   vanTellingen, Olaf ^a   Jonkers, Jos ^a   VanLohuizen, Maarten ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; SHORT HAIRPIN RNA; TEMOZOLOMIDE; TRANSCRIPTION FACTOR EZH2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL DEDIFFERENTIATION; CELL FATE; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; EPIGENETICS; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PLURIPOTENT STEM CELL; PROLONGED PROTEIN DEPLETION; PROTEIN DEPLETION; TUMOR DIFFERENTIATION; TUMOR GROWTH;

EID: 84921412405     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.12.028     Document Type: Article

References (50)

1. Adams B.R., Golding S.E., Rao R.R., Valerie K. Dynamic dependence on ATR and ATM for double-strand break repair in human embryonic stem cells and neural descendants. PLoS ONE 2010, 5:e10001.
2. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
3. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome-biological and translational implications. Nat. Rev. Cancer 2011, 11:726-734.
4. Ben-Porath I., Thomson M.W., Carey V.J., Ge R., Bell G.W., Regev A., Weinberg R.A. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 2008, 40:499-507.
5. Bender S., Tang Y., Lindroth A.M., Hovestadt V., Jones D.T., Kool M., Zapatka M., Northcott P.A., Sturm D., Wang W., et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 2013, 24:660-672.
6. Bruggeman S.W., Valk-Lingbeek M.E., van der Stoop P.P., Jacobs J.J., Kieboom K., Tanger E., Hulsman D., Leung C., Arsenijevic Y., Marino S., van Lohuizen M. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev. 2005, 19:1438-1443.
7. Bruggeman S.W., Hulsman D., Tanger E., Buckle T., Blom M., Zevenhoven J., van Tellingen O., van Lohuizen M. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 2007, 12:328-341.
8. Campbell S., Ismail I.H., Young L.C., Poirier G.G., Hendzel M.J. Polycomb repressive complex 2 contributes to DNA double-strand break repair. Cell Cycle 2013, 12:2675-2683.
9. Chan K.M., Fang D., Gan H., Hashizume R., Yu C., Schroeder M., Gupta N., Mueller S., James C.D., Jenkins R., et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 2013, 27:985-990.
10. Chang C.J., Yang J.Y., Xia W., Chen C.T., Xie X., Chao C.H., Woodward W.A., Hsu J.M., Hortobagyi G.N., Hung M.C. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell 2011, 19:86-100.
11. Chase A., Cross N.C. Aberrations of EZH2 in cancer. Clin. Cancer Res. 2011, 17:2613-2618.
12. Chou D.M., Adamson B., Dephoure N.E., Tan X., Nottke A.C., Hurov K.E., Gygi S.P., Colaiácovo M.P., Elledge S.J. A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage. Proc. Natl. Acad. Sci. USA 2010, 107:18475-18480.
13. Crea F., Hurt E.M., Farrar W.L. Clinical significance of Polycomb gene expression in brain tumors. Mol. Cancer 2010, 9:265.
14. de Vries N.A., Bruggeman S.W., Hulsman D., de Vries H.I., Zevenhoven J., Buckle T., Hamans B.C., Leenders W.P., Beijnen J.H., van Lohuizen M., et al. Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies. Clin. Cancer Res. 2010, 16:3431-3441.
15. Ernst T., Chase A.J., Score J., Hidalgo-Curtis C.E., Bryant C., Jones A.V., Waghorn K., Zoi K., Ross F.M., Reiter A., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 2010, 42:722-726.
16. Fragola G., Germain P.L., Laise P., Cuomo A., Blasimme A., Gross F., Signaroldi E., Bucci G., Sommer C., Pruneri G., et al. Cell reprogramming requires silencing of a core subset of polycomb targets. PLoS Genet. 2013, 9:e1003292.
17. Friedmann-Morvinski D., Bushong E.A., Ke E., Soda Y., Marumoto T., Singer O., Ellisman M.H., Verma I.M. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 2012, 338:1080-1084.
18. González F., Georgieva D., Vanoli F., Shi Z.D., Stadtfeld M., Ludwig T., Jasin M., Huangfu D. Homologous recombination DNA repair genes play a critical role in reprogramming to a pluripotent state. Cell Rep. 2013, 3:651-660.
19. Guo Y., Liu S., Wang P., Zhao S., Wang F., Bing L., Zhang Y., Ling E.A., Gao J., Hao A. Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology 2011, 59:763-775.
20. Helin K., Dhanak D. Chromatin proteins and modifications as drug targets. Nature 2013, 502:480-488.
21. Herold M.J., van den Brandt J., Seibler J., Reichardt H.M. Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats. Proc. Natl. Acad. Sci. USA 2008, 105:18507-18512.
22. Holmberg J., He X., Peredo I., Orrego A., Hesselager G., Ericsson C., Hovatta O., Oba-Shinjo S.M., Marie S.K., Nistér M., Muhr J. Activation of neural and pluripotent stem cell signatures correlates with increased malignancy in human glioma. PLoS ONE 2011, 6:e18454.
23. Huang F., Motlekar N.A., Burgwin C.M., Napper A.D., Diamond S.L., Mazin A.V. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem. Biol. 2011, 6:628-635.
24. Kawamura T., Suzuki J., Wang Y.V., Menendez S., Morera L.B., Raya A., Wahl G.M., Izpisúa Belmonte J.C. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009, 460:1140-1144.
25. Le Scodan R., Cizeron-Clairac G., Fourme E., Meseure D., Vacher S., Spyratos F., de la Lande B., Cvitkovic F., Lidereau R., Bieche I. DNA repair gene expression and risk of locoregional relapse in breast cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 2010, 78:328-336.
26. Lewis P.W., Müller M.M., Koletsky M.S., Cordero F., Lin S., Banaszynski L.A., Garcia B.A., Muir T.W., Becher O.J., Allis C.D. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013, 340:857-861.
27. Li H., Collado M., Villasante A., Strati K., Ortega S., Cañamero M., Blasco M.A., Serrano M. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009, 460:1136-1139.
28. Li G., Warden C., Zou Z., Neman J., Krueger J.S., Jain A., Jandial R., Chen M. Altered expression of polycomb group genes in glioblastoma multiforme. PLoS ONE 2013, 8:e80970.
29. Mao X.G., Hütt-Cabezas M., Orr B.A., Weingart M., Taylor I., Rajan A.K., Odia Y., Kahlert U., Maciaczyk J., Nikkhah G., et al. LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program. Oncotarget 2013, 4:1050-1064.
30. Margueron R., Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011, 469:343-349.
31. Momcilovic O., Knobloch L., Fornsaglio J., Varum S., Easley C., Schatten G. DNA damage responses in human induced pluripotent stem cells and embryonic stem cells. PLoS ONE 2010, 5:e13410.
32. Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R., Paul J.E., Boyle M., Woolcock B.W., Kuchenbauer F., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 2010, 42:181-185.
33. Natsume A., Ito M., Katsushima K., Ohka F., Hatanaka A., Shinjo K., Sato S., Takahashi S., Ishikawa Y., Takeuchi I., et al. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma. Cancer Res. 2013, 73:4559-4570.
34. Orzan F., Pellegatta S., Poliani P.L., Pisati F., Caldera V., Menghi F., Kapetis D., Marras C., Schiffer D., Finocchiaro G. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol. Appl. Neurobiol. 2011, 37:381-394.
35. Qiao G.B., Wu Y.L., Yang X.N., Zhong W.Z., Xie D., Guan X.Y., Fischer D., Kolberg H.C., Kruger S., Stuerzbecher H.W. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br. J. Cancer 2005, 93:137-143.
36. Quiros S., Roos W.P., Kaina B. Rad51 and BRCA2-New molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS ONE 2011, 6:e27183.
37. Rais Y., Zviran A., Geula S., Gafni O., Chomsky E., Viukov S., Mansour A.A., Caspi I., Krupalnik V., Zerbib M., et al. Deterministic direct reprogramming of somatic cells to pluripotency. Nature 2013, 502:65-70.
38. Roos W.P., Nikolova T., Quiros S., Naumann S.C., Kiedron O., Zdzienicka M.Z., Kaina B. Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair (Amst.) 2009, 8:72-86.
39. Sancho-Martinez I., Izpisua Belmonte J.C. Stem cells: Surf the waves of reprogramming. Nature 2013, 493:310-311.
40. Sher F., Rössler R., Brouwer N., Balasubramaniyan V., Boddeke E., Copray S. Differentiation of neural stem cells into oligodendrocytes: involvement of the polycomb group protein Ezh2. Stem Cells 2008, 26:2875-2883.
41. Silva J., Barrandon O., Nichols J., Kawaguchi J., Theunissen T.W., Smith A. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol. 2008, 6:e253.
42. Simon J.A., Lange C.A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 2008, 647:21-29.
43. Simon C., Chagraoui J., Krosl J., Gendron P., Wilhelm B., Lemieux S., Boucher G., Chagnon P., Drouin S., Lambert R., et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev. 2012, 26:651-656.
44. Sparmann A., van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 2006, 6:846-856.
45. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N.Engl. J. Med. 2005, 352:987-996. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials GroupNational Cancer Institute of Canada Clinical Trials Group.
46. Suvà M.L., Riggi N., Janiszewska M., Radovanovic I., Provero P., Stehle J.C., Baumer K., Le Bitoux M.A., Marino D., Cironi L., et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 2009, 69:9211-9218.
47. Tsaryk R., Fabian K., Thacker J., Kaina B. Xrcc2 deficiency sensitizESCs to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide. Cancer Lett. 2006, 239:305-313.
48. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110. Cancer Genome Atlas Research Network.
49. Vispé S., Cazaux C., Lesca C., Defais M. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res. 1998, 26:2859-2864.
50. Viswanathan S.R., Powers J.T., Einhorn W., Hoshida Y., Ng T.L., Toffanin S., O'Sullivan M., Lu J., Phillips L.A., Lockhart V.L., et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat. Genet. 2009, 41:843-848.